BioTech
-
FDA approves Moderna’s RSV vaccine, its second licensed product
The Food and Drug Administration on Friday approved Moderna’s vaccine to protect older adults against respiratory syncytial virus, or RSV,…
Read More » -
Pfizer’s Lorbrena, Ultragenyx, Ionis, Sarepta
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
For one rare type of lung cancer, Pfizer pill reduces progression by 81%
There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might…
Read More » -
Ionis drug prevents swelling attacks due to hereditary angioedema
Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of…
Read More » -
Ultragenyx gene therapy for rare liver ailment succeeds in late-stage trial
Ultragenyx said Thursday afternoon that its gene therapy for a rare liver ailment, glycogen disease type 1A, succeeded in a…
Read More » -
Moderna bird flu vaccine, Biohaven, ASCO
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
STAT+: Did Sarepta Therapeutics earn $4 billion from exon-skipping drugs that don’t work?
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it…
Read More » -
Biohaven protein-degrader drug falls short of investor expectations in early test
Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up…
Read More » -
Wegovy, Merck, Gameto, and Neurocrine
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
Insmed, Asahi Kasei, Agios, Royalty Pharma
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More »